Rare Genomics Board of Directors
Jimmy Lin
C. Jimmy Lin, MD, PhD, MHS is the Founder & CEO of Rare Genomics Institute, the world's first platform to enable any community to leverage cutting- edge biotechnology to advance understanding of any rare disease. He is also the Chief Scientific Officer (CSO) at Freenome, working on early diagnostic of cancers. Previously, he was the CSO, Oncology at Natera (NASDAQ: NTRA), where he is led the development of new diagnostic technologies for cancer. Previously, Dr. Lin led the ClinOmics program in the Genetics Branch of the National Cancer Institute (NIH/NCI). Prior to this, he led the computational analysis of the first ever exome sequencing studies of cancer at Johns Hopkins and was a research instructor at Washington University in St. Louis. He has numerous publications in Science, Nature, Cell, Nature Genetics, and Nature Biotechnology, and has been featured in Forbes, Bloomberg, Wall Street Journal, New York Times, Washington Post, BBC, TIME, and the Huffington Post.
Joe Beery
Joseph Beery serves on the advisory boards of Biola University and the UC San Diego Jacobs School of Engineering, as well as the corporate boards of Intuitive Surgical, MedCrypt Inc. and R-STOR Inc. He is an active member of the board for the Rady Children’s Institute for Genomic Medicine and Hope Knows No Boundaries, a patient advocacy non-profit. Prior to joining RG, Mr. Beery served as CIO for Thermo Fisher Scientific, Life Technologies, US Airways, and America West Airlines. He has been honored in the “San Diego Business Journal’s Top 500” four years in a row, and is a recipient of a CIO 100 Award. Mr. Beery has earned a reputation as a transformational IT executive and thought leader in the field, with features in CIO Magazine, Hispanic Executive, The Wall Street Journal, and Nature.
Hugh Rienhoff
Hugh Rienhoff, MD is the founder and CEO of Imago BioSciences, a clinical stage company focused on hematologic diseases. Prior to founding Imago, Dr. Reinhoff founded and was CEO of DNA Sciences (f/k/a Kiva Genetics) and FerroKin BioSciences. Additionally, he served as founding director of Healtheon/WebMD (HLTH) and Aurora Biosciences (ABSC). Dr. Reinhoff trained in mathematics, medicine and genetics at Harvard University, Johns Hopkins University and the Fred Hutchison Cancer Research Center in Seattle, Washington. He received a Doctor of Medicine degree from Johns Hopkins University School of Medicine and a Bachelor of Arts degree in Biology and English Literature from Williams College.
Imran Babar, PhD
Imran Babar, PhD is the CBO of Cydan, a venture-backed orphan drug accelerator and Co-Founder & CBO of Tiburio, an orphan endocrinology spin-out from Cydan. Prior to joining Cydan, Dr. Babar worked with the private equity team at OrbiMed Advisors, a leading healthcare investment firm, as well as the equity research team at Cowen & Company. A Howard Hughes Medical Institute Fellow and a Harvey Fellow, Dr. Babar completed his PhD in Molecular Biology at Yale, his BA in Biology at Carleton College and has conducted research with the Massachusetts Institute of Technology (MIT) and the National Institutes of Health (NIH).